scholarly journals Genomic Profiling and Clinicopathological Characteristics of Neuroendocrine Tumors of the Lung in East Asian Patients

In Vivo ◽  
2020 ◽  
Vol 34 (6) ◽  
pp. 3375-3385
Author(s):  
MOONSIK KIM ◽  
YEON SEUNG CHUNG ◽  
KYOUNG A KIM ◽  
HYO SUP SHIM
2017 ◽  
Vol 108 (12) ◽  
pp. 2487-2494 ◽  
Author(s):  
Liping Liu ◽  
Jilong Liu ◽  
Di Shao ◽  
Qiuhua Deng ◽  
Hailing Tang ◽  
...  

2019 ◽  
Vol Volume 12 ◽  
pp. 1717-1728 ◽  
Author(s):  
James C Yao ◽  
Do-Youn Oh ◽  
Jiaming Qian ◽  
Young Suk Park ◽  
Fabian Herbst ◽  
...  

2021 ◽  
Vol 16 (3) ◽  
pp. S562-S563
Author(s):  
H. Feng ◽  
C. Xu ◽  
W. Wang ◽  
D. Wang ◽  
Y. Zhu ◽  
...  

2021 ◽  
Author(s):  
Toshio Shimizu ◽  
Yasutoshi Kuboki ◽  
Chia-Chi Lin ◽  
Kan Yonemori ◽  
Tomoko Yanai ◽  
...  

2013 ◽  
Vol 24 ◽  
pp. ix48
Author(s):  
W.S. Kim ◽  
K. Venkatakrishnan ◽  
T.M. Kim ◽  
C.-C. Lin ◽  
L.S. Thye ◽  
...  

2021 ◽  
Author(s):  
Jean Zhao ◽  
Sheng Zhong ◽  
Bo Wu ◽  
Frank Dubois ◽  
Shanshan Jiang ◽  
...  

Abstract While it is well known that Glioblastoma (GBM) shows profound inter- and intra-tumoral heterogeneity, disparities in molecular features across ancestry groups have been largely overlooked. We collected a large cohort of GBM samples from East Asian patients (EAS-GBM) and performed genomic and transcriptomic analyses of these samples (EAS-GBM, n=443). Further characterization and comparative analysis of the EAS-GBM with the predominantly European-ancestry TCGA GBM dataset (EUR-GBM, n=383) revealed differential genomic and genetic landscape and immunological profile of EAS-GBM from EUR-GBM. EAS-GBM showed an enrichment for NF1, H3F3A, TP53 and ATRX mutations compared to EUR-GBM. Transcriptomic clustering revealed distinct EAS-GBM specific subtypes, namely Proliferative (PL), Neuron-Synaptic (NS), Metabolic (MB) and Immunomodulatory (IM). Notably, the classic subtype of EUR-GBMs with EGFR as its main marker gene was absent in EAS-GBMs, Moreover, the IM subgroup in EAS-GBM with an expression profile that has been previously associated with response to immunotherapy in cancers. Together, our comprehensive characterization revealed the unique genomic and genetic features of EAS-GBMs, providing mechanistic rationale in patient stratification for molecular targeted therapy and drug development in the era of personalized medicine.


Sign in / Sign up

Export Citation Format

Share Document